These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 22825844)

  • 1. Current statin usage for patients with acute coronary syndrome undergoing percutaneous coronary intervention: multicenter survey in Korea.
    Kim MJ; Jeon DS; Gwon HC; Kim SJ; Chang K; Kim HS; Tahk SJ;
    Clin Cardiol; 2012 Nov; 35(11):700-6. PubMed ID: 22825844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial.
    Sardella G; Lucisano L; Mancone M; Conti G; Calcagno S; Stio RE; Pennacchi M; Biondi-Zoccai G; Canali E; Fedele F
    Int J Cardiol; 2013 Oct; 168(4):3715-20. PubMed ID: 23849964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome).
    Leoncini M; Toso A; Maioli M; Tropeano F; Villani S; Bellandi F
    J Am Coll Cardiol; 2014 Jan 7-14; 63(1):71-9. PubMed ID: 24076283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-cIN trial).
    Kaya A; Kurt M; Tanboğa IH; Işik T; Ekinci M; Aksakal E; Kaya Y; Topçu S; Sevimli S
    Acta Cardiol; 2013 Oct; 68(5):489-94. PubMed ID: 24283110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.
    Gibson CM; Pride YB; Hochberg CP; Sloan S; Sabatine MS; Cannon CP;
    J Am Coll Cardiol; 2009 Dec; 54(24):2290-5. PubMed ID: 19958964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between inflammation and benefits of early high-dose rosuvastatin on contrast-induced nephropathy in patients with acute coronary syndrome: the pathophysiological link in the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention).
    Toso A; Leoncini M; Maioli M; Tropeano F; Di Vincenzo E; Villani S; Bellandi F
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1421-9. PubMed ID: 25523533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial.
    Kim JS; Kim J; Choi D; Lee CJ; Lee SH; Ko YG; Hong MK; Kim BK; Oh SJ; Jeon DW; Yang JY; Cho JR; Lee NH; Cho YH; Cho DK; Jang Y
    JACC Cardiovasc Interv; 2010 Mar; 3(3):332-9. PubMed ID: 20298994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preloading with atorvastatin before percutaneous coronary intervention in statin-naïve Asian patients with non-ST elevation acute coronary syndromes: A randomized study.
    Jang Y; Zhu J; Ge J; Kim YJ; Ji C; Lam W
    J Cardiol; 2014 May; 63(5):335-43. PubMed ID: 24216317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy of rosuvastatin versus atorvastatin in preventing contrast induced nephropathy in patient with chronic kidney disease undergoing percutaneous coronary intervention.
    Liu Y; Liu YH; Tan N; Chen JY; Zhou YL; Li LW; Duan CY; Chen PY; Luo JF; Li HL; Wei-Guo
    PLoS One; 2014; 9(10):e111124. PubMed ID: 25357250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporal trends in the use of high-dose potent statins following acute coronary syndrome in Israel.
    Elis A; Pereg D; Dicker D; Gevrielov-Yusim N; Goldenberg I; Matetzky S; Kopel E; Klempfner R
    Cardiology; 2014; 128(3):266-72. PubMed ID: 24863615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a single high loading dose of rosuvastatin on percutaneous coronary intervention for acute coronary syndromes.
    Wang Z; Dai H; Xing M; Yu Z; Lin X; Wang S; Zhang J; Hou F; Ma Y; Ren Y; Tan K; Wang Y; Ge Z
    J Cardiovasc Pharmacol Ther; 2013 Jul; 18(4):327-33. PubMed ID: 23364255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome.
    Yun KH; Jeong MH; Oh SK; Rhee SJ; Park EM; Lee EM; Yoo NJ; Kim NH; Ahn YK; Jeong JW
    Int J Cardiol; 2009 Nov; 137(3):246-51. PubMed ID: 18706705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial.
    Eisen A; Cannon CP; Braunwald E; Steen DL; Zhou J; Goodrich EL; Im K; Dalby AJ; Spinar J; Daga S; Lukas MA; O'Donoghue ML
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28077384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of high-dose atorvastatin or rosuvastatin loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials with GRADE qualification of available evidence.
    Borovac JA; Leth-Olsen M; Kumric M; D'Amario D; Schwarz K; Glavas D; Bozic J
    Eur J Clin Pharmacol; 2022 Jan; 78(1):111-126. PubMed ID: 34423376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lipid-lowering therapy and patient adherence in the MULTI GAP 2013 trial].
    Simonyi G
    Orv Hetil; 2014 Apr; 155(17):669-75. PubMed ID: 24755449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early high-dose rosuvastatin and cardioprotection in the protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome (PRATO-ACS) study.
    Leoncini M; Toso A; Maioli M; Tropeano F; Badia T; Villani S; Bellandi F
    Am Heart J; 2014 Nov; 168(5):792-7. PubMed ID: 25440809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of high-dose statin pre-treatment and contrast-induced acute kidney injury on follow-up events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Patti G; Leoncini M; Toso A; Maioli M; Grieco D; Colonna G; Bellandi F; Di Sciascio G
    Int J Cardiol; 2014 Jun; 174(2):440-1. PubMed ID: 24767765
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial.
    Zhao SP; Yu BL; Peng DQ; Huo Y
    Atherosclerosis; 2014 Apr; 233(2):707-712. PubMed ID: 24603217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy.
    Puri R; Nissen SE; Libby P; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    Circulation; 2013 Nov; 128(22):2395-403. PubMed ID: 24043299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Non-ST-elevation acute coronary syndrome. Comparison of effects of atorvastatin and rosuvastatin on blood levels of lipids and markers of inflammation].
    Kuznetsova MA; Vaulin NA; Masenko VP; Gratsianskiĭ NA
    Kardiologiia; 2010; 50(2):21-5. PubMed ID: 20146674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.